{"id":401519,"date":"2020-12-17T02:03:17","date_gmt":"2020-12-17T07:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=401519"},"modified":"2020-12-17T02:03:17","modified_gmt":"2020-12-17T07:03:17","slug":"poxel-announces-participation-at-upcoming-virtual-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/","title":{"rendered":"Poxel Announces Participation at Upcoming Virtual Investor Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\" style=\"font-weight:normal\"><b>Poxel Announces Participation at Upcoming Virtual Investor Conferences<\/b><\/p>\n<p>LYON, France&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxel.com%2F&amp;esheet=52349801&amp;newsitemid=20201216005798&amp;lan=en-US&amp;anchor=POXEL+SA&amp;index=1&amp;md5=1a3d4110f9dd38527e3ff19df06bac0c\">POXEL SA<\/a> (Euronext: POXEL &#8211; FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management team will participate at several upcoming virtual investor conferences that will be held in January 2021.\n<\/p>\n<p><b>2021 ODDO BHF Digital Forum<br \/>\n<br \/>Date<\/b>: January 7-13, 2021<br \/>\n<br \/>Thomas Kuhn, Chief Executive Officer of Poxel, and Anne Renevot, Chief Financial Officer, will be available for one-on-one virtual meetings.\n<\/p>\n<p><b>2021 Degroof Petercam Healthcare Conference<br \/>\n<br \/>Date<\/b>: January 28, 2021<br \/>\n<br \/>Thomas Kuhn, Chief Executive Officer of Poxel, David Moller, MD, Executive Vice President and Chief Scientific Officer and Anne Renevot, Chief Financial Officer, will be available for one-on-one virtual meetings.\n<\/p>\n<p><b>About Poxel SA<br \/>\n<br \/><\/b>Poxel is a <b>dynamic biopharmaceutical company<\/b> that uses its extensive expertise in developing <b>innovative drugs for metabolic diseases<\/b>, with a focus on <b>type 2 diabetes<\/b> and <b>non-alcoholic steatohepatitis (NASH)<\/b>. In its mid-to-late-stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. <b>Imeglimin<\/b>, Poxel\u2019s first-in-class lead product, targets mitochondrial dysfunction. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. A Japanese new drug application (J-NDA) is under review by the Pharmaceuticals and Medical Devices Agency (PMDA) to request approval for the manufacturing and marketing of Imeglimin for the treatment of type 2 diabetes. After successfully completing a Phase 2a proof-of-concept trial for the treatment of NASH, which met its primary endpoint and study objectives, for<b> PXL770<\/b>, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, Poxel plans to initiate a Phase 2b program in the second half of 2021. PXL770 could also have the potential to treat additional metabolic diseases. <b>PXL065<\/b> (deuterium-stabilized R-pioglitazone), a MPC inhibitor, is in a streamlined Phase 2 trial for the treatment of NASH. Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=52349801&amp;newsitemid=20201216005798&amp;lan=en-US&amp;anchor=www.poxelpharma.com&amp;index=2&amp;md5=7b2e5f2a15c62fcfeaa6b91ec48871c4\">www.poxelpharma.com<\/a>.\n<\/p>\n<p>\nIn the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business.\n<\/p>\n<p>\nAs of the date of this press release, and based on publicly available information, the Company has not identified the occurrence of any material negative effect on its business due to the COVID-19 pandemic that remains unresolved. However, the Company anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company\u2019s internal organization and efficiency, particularly in countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19 may impact market conditions and the Company\u2019s ability to seek additional funding or enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical and\/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company\u2019s development programs and partnered programs. The Company will continue to actively monitor the situation.\n<\/p>\n<p>\nAll statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company\u2019s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould\u201d and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company\u2019s control that could cause the Company\u2019s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201216005798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201216005798\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201216005798\/en\/<\/a><\/span><\/p>\n<p><b>Poxel SA<br \/>\n<\/b><br \/>Jonae R. Barnes<br \/>\n<br \/>Senior Vice President, Investor Relations, Corporate Communications and Public Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jonae.barnes@poxelpharma.com\">jonae.barnes@poxelpharma.com<br \/>\n<\/a><br \/>+1 617 818 2985\n<\/p>\n<p>\nAur\u00e9lie Bozza<br \/>\n<br \/>Investor Relations &amp; Communication Director<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:aurelie.bozza@poxelpharma.com\">aurelie.bozza@poxelpharma.com<br \/>\n<\/a><br \/>+33 6 99 81 08 36\n<\/p>\n<p><b>Investor relations \/ Media &#8211; EU\/US<br \/>\n<\/b><br \/>Trophic Communications<br \/>\n<br \/>Stephanie May or Valeria Fisher<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:may@trophic.eu\">may@trophic.eu<\/a> or <a rel=\"nofollow\" href=\"mailto:fisher@trophic.eu\">fisher@trophic.eu<br \/>\n<\/a><br \/>+49 171 185 56 82 or +49 175 804 1816\n<\/p>\n<p><b>Investor relations \/ Media &#8211; France<br \/>\n<\/b><br \/>NewCap<br \/>\n<br \/>Emmanuel Huynh or Arthur Rouill\u00e9<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:poxel@newcap.eu\">poxel@newcap.eu<br \/>\n<\/a><br \/>+33 1 44 71 94 94\n<\/p>\n<p><b>KEYWORDS:<\/b> France Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Diabetes Other Health Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201216005798\/en\/729413\/3\/Logo_Without_Background.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Poxel Announces Participation at Upcoming Virtual Investor Conferences LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management team will participate at several upcoming virtual investor conferences that will be held in January 2021. 2021 ODDO BHF Digital Forum Date: January 7-13, 2021 Thomas Kuhn, Chief Executive Officer of Poxel, and Anne Renevot, Chief Financial Officer, will be available for one-on-one virtual meetings. 2021 Degroof Petercam Healthcare Conference Date: January 28, 2021 Thomas Kuhn, Chief Executive Officer of Poxel, David Moller, MD, Executive Vice President and Chief Scientific Officer and Anne Renevot, Chief &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Poxel Announces Participation at Upcoming Virtual Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-401519","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Poxel Announces Participation at Upcoming Virtual Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poxel Announces Participation at Upcoming Virtual Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Poxel Announces Participation at Upcoming Virtual Investor Conferences LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management team will participate at several upcoming virtual investor conferences that will be held in January 2021. 2021 ODDO BHF Digital Forum Date: January 7-13, 2021 Thomas Kuhn, Chief Executive Officer of Poxel, and Anne Renevot, Chief Financial Officer, will be available for one-on-one virtual meetings. 2021 Degroof Petercam Healthcare Conference Date: January 28, 2021 Thomas Kuhn, Chief Executive Officer of Poxel, David Moller, MD, Executive Vice President and Chief Scientific Officer and Anne Renevot, Chief &hellip; Continue reading &quot;Poxel Announces Participation at Upcoming Virtual Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-17T07:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201216005798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Poxel Announces Participation at Upcoming Virtual Investor Conferences\",\"datePublished\":\"2020-12-17T07:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/\"},\"wordCount\":790,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201216005798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/\",\"name\":\"Poxel Announces Participation at Upcoming Virtual Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201216005798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-17T07:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201216005798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201216005798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poxel Announces Participation at Upcoming Virtual Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poxel Announces Participation at Upcoming Virtual Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Poxel Announces Participation at Upcoming Virtual Investor Conferences - Market Newsdesk","og_description":"Poxel Announces Participation at Upcoming Virtual Investor Conferences LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management team will participate at several upcoming virtual investor conferences that will be held in January 2021. 2021 ODDO BHF Digital Forum Date: January 7-13, 2021 Thomas Kuhn, Chief Executive Officer of Poxel, and Anne Renevot, Chief Financial Officer, will be available for one-on-one virtual meetings. 2021 Degroof Petercam Healthcare Conference Date: January 28, 2021 Thomas Kuhn, Chief Executive Officer of Poxel, David Moller, MD, Executive Vice President and Chief Scientific Officer and Anne Renevot, Chief &hellip; Continue reading \"Poxel Announces Participation at Upcoming Virtual Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-17T07:03:17+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201216005798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Poxel Announces Participation at Upcoming Virtual Investor Conferences","datePublished":"2020-12-17T07:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/"},"wordCount":790,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201216005798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/","name":"Poxel Announces Participation at Upcoming Virtual Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201216005798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-17T07:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201216005798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201216005798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-announces-participation-at-upcoming-virtual-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Poxel Announces Participation at Upcoming Virtual Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=401519"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401519\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=401519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=401519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=401519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}